Analysts at H.C. Wainwright Foresee Rapid Growth for Harrow (HROW), Driven by its Portfolio of Branded Ophthalmology Products. The Stock has Room for up to $57 (+85%)
Reading Time: 2 minutes
Harrow (HROW) is a USA-based pharmaceutical company specialized in ophthalmology. After a sixfold increase in the share price over the past year, the stock is currently undergoing sharp consolidation. This may now come to an end following an analyst's commentary. H.C. Wainwright initiates coverage with a buy recommendation and a price target of $57. The upside potential is 85%. Harrow is described as a commercial-stage company focusing on the development and marketing of ophthalmic pharmaceutical products for the US market. Analysts foresee rapid...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
